14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ANRO vs COCP: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Alto Neuroscience Inc. (ANRO) is the stronger overall head-to-head candidate over Cocrystal Pharma, Inc. (COCP) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). ANRO carries a Unified Composite Score of 29.3/100 (SELL) at $27.77 (N/M Forward P/E, 0.0% operating margin), whereas COCP carries 47.1/100 (HOLD) at $1.00 (N/M Forward P/E, -3063.6% operating margin).
Composite vs. Pillar Nuance: While COCP currently prints a higher short-term Unified Composite Score (47.1/100 HOLD vs. ANRO 29.3/100 SELL), ANRO captures the overall institutional head-to-head verdict (4–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -3063.6% operating margin) and revenue trajectory (+0.0% vs. +26.9% YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ANRO vs COCP. Trailing 12-month operating profitability (ANRO 0.0% vs COCP -3063.6%) and valuation multiples (ANRO N/M vs COCP N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $19.6M market capitalization and -3063.6% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ANRO vs COCP Key Questions & Quantitative Answers
As of Nov 16, 2026, Alto Neuroscience Inc. (ANRO) is the stronger overall head-to-head candidate over Cocrystal Pharma, Inc. (COCP) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). ANRO carries a Unified Composite Score of 29.3/100 (SELL) at $27.77 (N/M Forward P/E, 0.0% operating margin), whereas COCP carries 47.1/100 (HOLD) at $1.00 (N/M Forward P/E, -3063.6% operating margin). Composite vs. Pillar Nuance: While COCP currently prints a higher short-term Unified Composite Score (47.1/100 HOLD vs. ANRO 29.3/100 SELL), ANRO captures the overall institutional head-to-head verdict (4–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -3063.6% operating margin) and revenue trajectory (+0.0% vs. +26.9% YoY).
COCP leads the Growth & Scale pillar: ANRO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with COCP at +26.9% YoY revenue growth and +0.0% YoY earnings growth on $330,000 TTM revenue (N/A gross margin, -3063.6% operating margin). On trailing 12-month operating scale, ANRO generates N/A in USD-normalized revenue versus $330,000 for COCP. In operating R&D and SG&A reinvestment, ANRO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for COCP.
COCP screens cheaper on headline valuation multiples. ANRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas COCP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 49.7x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ANRO (-46.7% ROE) versus COCP (-311.7% ROE) capital efficiency.
In options market volatility and institutional positioning, ANRO carries 79.4% implied volatility (8th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.95β · 89% Vol realized risk). By comparison, COCP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.04β · 54% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.